Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

The 2025 top 50 saw four new entrants: Caterpillar (#40), ServiceNow (#42), Taiwan Semiconductor (#45), and Novo Nordisk (#46 ... Korn Ferry is a global organizational consulting firm.

Novo Banco accessed the covered bond market on Tuesday for the first time since its debut last year. It raised a tight €500m February 2030 Obrigações Cobertas backed by a strong €3.8bn final ...

"All chronic kidney disease is progressive. It's a year-on-year, relentless decline in renal function," Stephen Gough, Novo Nordisk's global chief medical officer, said in an interview, referring ...

The Danish drug giant Novo Nordisk, known for its antidiabetes and weight loss drugs such as semaglutide (Ozempic or Wegovy), has been censured by the UK’s Prescription Medicines Code of Practice ...

“We are very encouraged by the subcutaneous phase 1b/2a results for amycretin in people living with overweight or obesity,” said Martin Lange, executive vice president for Development at Novo Nordisk.

Global growth is projected at 3.3 percent both in 2025 and 2026, below the historical (2000–19) average of 3.7 percent. The forecast for 2025 is broadly unchanged from that in the October 2024 World ...

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk ... in people living with overweight or obesity,” said Martin Lange, executive vice president for Development at Novo Nordisk.

The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 people ... Novo Nordisk is a leading ...